BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 ...

Also highlight plans to integrated with Biocon at 44th Annual J.P. Morgan Healthcare Conference in San Francisco ...

Biocon Biologics is set to unveil three new biosimilar oncology assets — Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) — at the 2026 JP ...

Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and ...

In the trial, 38% of patients were still alive at 3 years with this dual immunotherapy vs. 24% with the comparator arm 1 OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...